# Vertex Pharmaceuticals (VRTX) revenue: $12.00B in 2025

URL: https://funkfolio.com/stock/VRTX/revenue

> Vertex Pharmaceuticals (VRTX) revenue was $12.00B in fiscal 2025, up 8.9% from fiscal 2024. Over five fiscal years it grew 14.1% a year.

---

## Vertex Pharmaceuticals (VRTX) revenue

**Revenue · fiscal 2025:** $12.00B year ended Dec 31, 2025

Vertex Pharmaceuticals (VRTX) reported revenue of $12.00B in fiscal 2025 (the year ended December 31, 2025). That is 8.9% higher than the $11.02B of fiscal 2024. Figures as of 18 Nov 2026, 09:40 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Revenue, fiscal 2025:** $12.00B
- **Change on fiscal 2024:** +8.9%
- **Growth, 5 years:** +14.1% a year
- **Growth, 10 years:** +27.8% a year
- **Highest on record:** $12.00B fiscal 2025
- **Lowest on record:** $101.89M fiscal 2009
- **Fiscal years on record:** 18 2008–2025

Figures as of 18 Nov 2026, 09:40 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Vertex Pharmaceuticals revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 14.1% a year; over ten years the rate was 27.8% a year. Across the 18 fiscal years on record (2008–2025), the highest was $12.00B in fiscal 2025 and the lowest $101.89M in fiscal 2009.

### Revenue by fiscal year

### Vertex Pharmaceuticals revenue, year by year

Vertex Pharmaceuticals (VRTX) revenue by fiscal year

| Fiscal year | Revenue | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $12.00B | 8.9% up | Dec 31, 2025 |
| 2024 | $11.02B | 11.7% up | Dec 31, 2024 |
| 2023 | $9.87B | 10.5% up | Dec 31, 2023 |
| 2022 | $8.93B | 17.9% up | Dec 31, 2022 |
| 2021 | $7.57B | 22.1% up | Dec 31, 2021 |
| 2020 | $6.21B | 49.1% up | Dec 31, 2020 |
| 2019 | $4.16B | 36.6% up | Dec 31, 2019 |
| 2018 | $3.05B | 22.5% up | Dec 31, 2018 |
| 2017 | $2.49B | 46.2% up | Dec 31, 2017 |
| 2016 | $1.70B | 64.9% up | Dec 31, 2016 |
| 2015 | $1.03B | 77.9% up | Dec 31, 2015 |
| 2014 | $580.42M | 52.1% down | Dec 31, 2014 |
| 2013 | $1.21B | 20.6% down | Dec 31, 2013 |
| 2012 | $1.53B | 8.3% up | Dec 31, 2012 |
| 2011 | $1.41B | 883.9% up | Dec 31, 2011 |
| 2010 | $143.37M | 40.7% up | Dec 31, 2010 |
| 2009 | $101.89M | 41.9% down | Dec 31, 2009 |
| 2008 | $175.50M | — | Dec 31, 2008 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

### How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

### Revenue at health care companies of similar size

Revenue of Vertex Pharmaceuticals and comparable companies

| Company | Revenue | Fiscal year |
| --- | --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/revenue) | $62.58B | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/revenue) | $24.57B | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/revenue) | $10.06B | 2025 |
| Vertex Pharmaceuticals VRTX | $12.00B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/revenue) | $36.36B | 2026 |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/revenue) | $48.20B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals earnings](https://funkfolio.com/stock/VRTX/earnings)
- [Vertex Pharmaceuticals earnings per share (EPS)](https://funkfolio.com/stock/VRTX/eps)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals P/B ratio](https://funkfolio.com/stock/VRTX/pb-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals cash on hand](https://funkfolio.com/stock/VRTX/cash)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals revenue: questions and answers

**What is Vertex Pharmaceuticals's revenue?**

Vertex Pharmaceuticals (VRTX) reported revenue of $12.00B in fiscal 2025 (the year ended December 31, 2025). That is 8.9% higher than the $11.02B of fiscal 2024.

**What is the growth rate of Vertex Pharmaceuticals's revenue?**

Over the five fiscal years to 2025 revenue grew at a compound 14.1% a year; over ten years the rate was 27.8% a year.

**What are the highest and lowest revenue figures on record for Vertex Pharmaceuticals?**

Across the 18 fiscal years on record (2008–2025), the highest was $12.00B in fiscal 2025 and the lowest $101.89M in fiscal 2009.

**How is Vertex Pharmaceuticals's revenue calculated?**

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Vertex Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: revenue

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.
